Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vertex Pharmaceuticals
Biotech
Vertex drops cell-device diabetes combo over poor ph. 1 results
Vertex is ending one of its two islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production.
James Waldron
Mar 31, 2025 4:20am
Vertex axes Verve gene editing pact amid shift in R&D priorities
Feb 27, 2025 9:05am
2024's top 10 clinical trial flops
Feb 18, 2025 3:00am
Vertex and Orna team up to develop new blood disorder treatments
Jan 7, 2025 7:00am
Vertex's pain prospect underwhelms versus placebo, sinking stock
Dec 19, 2024 7:41am
Novo Holdings-backed SiteOne charges up with $100M financing
Dec 18, 2024 7:00am
